FDA Greenlights Moderna: First mRNA Flu Vaccine Approved for Seniors

The U.S. Food and Drug Administration (FDA) approved the country’s first mRNA-based flu vaccine for adults aged 50 and older, marking a significant regulatory victory for Moderna amid a broader political crackdown on mRNA technology. The decision reverses an earlier rejection and signals a complex interplay between scientific data and the new health administration's agenda.

Moderna's mFLUSIVA Clears Regulatory Hurdles

Moderna announced that its mFLUSIVA shot is expected to be available for the 2026-2027 flu season, targeting a demographic vulnerable to severe influenza outcomes.

■The approval was backed by a Phase 3 trial of nearly 41,000 people aged 50-64, showing the vaccine is approximately 26.6% more effective than traditional flu shots.

■The FDA granted accelerated approval for adults 65 and older, contingent on favorable follow-up trial results, following a unanimous recommendation from its independent advisory committee.

■CEO Stéphane Bancel highlighted the platform's potential, stating the shot provides a crucial new option for America's seniors.

Navigating Political Headwinds in Washington

The approval follows a contentious period where the FDA faced backlash for initially refusing to review the shot, a move widely seen as influenced by Robert F. Kennedy Jr.'s skepticism towards mRNA technology.

■In February, the FDA rejected the review request based on objections from Dr. Vinay Prasad regarding the control vaccine used in trials, a stance that drew sharp criticism from the medical community.

■FDA Commissioner Marty Makary later walked back the refusal, characterizing the initial decision as part of standard regulatory dialogue.

■This occurs against the backdrop of Kennedy’s cancellation of $500 million in federal funding for mRNA vaccine research, a shift that former BARDA Director Rick Bright warned could cripple frontline defenses against biological threats.

Kemal Tekin Note: From a trading desk perspective, the FDA's reversal on Moderna highlights the volatility of "regulatory risk" as a distinct asset class factor. While the immediate clearance of mFLUSIVA provides a catalyst for Moderna shares, the broader policy environment in Washington—specifically the $500 million funding cut—creates a structural overhang for the mRNA sector. For emerging markets investors, this serves as a reminder that domestic policy shifts in the U.S. can rapidly alter the landscape for global biotech supply chains and R&D funding flows.